Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically-proven metastatic cancer of the colon or rectum.
Metastatic disease not amenable to potentially curative treatment (eg: inoperable metastatic disease).
Male or female aged \>18 years.
WHO Performance Status (PS) : 0 or 1.
Measurable disease.
No prior chemotherapeutic regimen for metastatic disease.
Disease-free interval from end of adjuvant therapy of at least 6 months (1 year if oxaliplatin was part of the adjuvant therapy).
Prior radiotherapy is permitted if it was not administered to target lesions identified for this study - unless progression within the radiation portal is documented - and provided it has been completed at least 3 weeks before randomization.
Signed written informed consent prior to study entry.
You may not be if
Any condition or past medical history that contra-indicates treatment with oxaliplatin and 5-FU, as reported in approved labeling information.
Received chemotherapeutic agents other than 5-FU, LV, Levamisole, irinotecan, capecitabine, oxaliplatin as part of adjuvant therapy.
Peripheral neuropathy \>Grade 1.
Concomitant treatments with drugs/ingredients reported to have a potential activity in preventing peripheral sensory neuropathy.
Concurrent active cancer originating from a primary site other than colon or rectum.
Presence of any symptom suggesting brain metastasis.
